Navigation Links
DOR BioPharma Announces Issuance of European Patent for its LPM(TM) Oral Drug Delivery Technology
Date:7/8/2009

a, Inc.'s current expectations about its future results, performance, prospects and opportunities. Statements that are not historical facts, such as "anticipates," "believes," "intends," or similar expressions, are forward-looking statements. These statements are subject to a number of risks, uncertainties and other factors that could cause actual events or results in future periods to differ materially from what is expressed in, or implied by, these statements. DOR cannot assure you that it will be able to successfully develop or commercialize products based on its technology, including orBec(R) and LPM(TM), particularly in light of the significant uncertainty inherent in developing vaccines against bioterror threats, manufacturing and conducting preclinical and clinical trials of vaccines, and obtaining regulatory approvals, that its cash expenditures will not exceed projected levels, that product development and commercialization efforts will not be reduced or discontinued due to difficulties or delays in clinical trials or due to lack of progress or positive results from research and development efforts, that it will be able to successfully obtain any further grants and awards, maintain its existing grants which are subject to performance, enter into any biodefense procurement contracts with the US Government or other countries, that the US Congress may not pass any legislation that would provide additional funding for the Project BioShield program, that it will be able to patent, register or protect its technology from challenge and products from competition or maintain or expand its license agreements with its current licensors, or that its business strategy will be successful. Important factors which may affect the future use of orBec(R) for gastrointestinal GVHD include the risks that: the FDA's requirement that DOR conduct additional clinical trials to demonstrate the safety and efficacy of orBec(R) will take a significant amount of time and money to
'/>"/>

SOURCE DOR BioPharma, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Morphotek(R), Inc. Announces a Research Collaboration Agreement with Synageva BioPharma Corporation to Develop Potential Treatments for Cancer and Infectious Disease
2. DOR BioPharma Announces Publication of orBec(R) Clinical Pulmonary Data in Bone Marrow Transplantation
3. Gyros Raises SEK 80 Million to Accelerate the Commercialization of its Gyrolab(R) Systems for the Cost-Efficient Development of Biopharmaceuticals
4. KBI Biopharma Starts Cell Line Generation Process under Vendor Network Agreement for PER.C6(R)
5. Helix BioPharma to Present L-DOS47 Analytical Method Development Findings at 2009 AAPS National Biotechnology Conference
6. Lytix Biopharma and KAEL-GemVax Announce Joint Clinical Trial to Combine LTX-315 and GV1001 Cancer Immunotherapy
7. Wound Management Technologies, Inc. Announced Today That It Has Reached an Agreement in Principal to Acquire BioPharma Management Technologies, Inc.
8. Helix BioPharma Announces Q3 2009 Financial Results and Provides Product Development Update
9. PDL BioPharma Provides Second Quarter 2009 Revenue Guidance of Approximately $125 Million
10. Keryx Biopharmaceuticals Reports Positive Phase 2 Study Results of Zerenex (Ferric Citrate) for the Treatment of Hyperphosphatemia in End-Stage Renal Disease Patients
11. Sinobiopharma Applies For Two Chinese Patents For Cisatracurium Besylate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/3/2015)... and CHICAGO , June 3, ... or "the Company"; LSE: CIR), a specialty biopharmaceutical company ... data relating to the Company,s novel immunotherapy candidates targeting ... presented at the 2015 European Academy of Allergy and ... Barcelona, Spain on 6-10 June. ...
(Date:6/3/2015)... Virginia (PRWEB) June 03, 2015 Photo-Eyewear™ ... changed its name to PogoTec™, Inc. ( http://www.PogoTec.com ... its electronic wearable device products and technologies it is ... creation of three business divisions, PogoTec™ will provide focused ... devices as follows: , , On-Track™ ...
(Date:6/3/2015)... June 03, 2015 Global Stem ... Inc. have announced plans to conduct Romania’s first ever ... Through an alliance with Miami-based Stem Cell Training, Inc., ... the Adipose and Bone Marrow Stem Cell Training Course ... reconstructive plastic surgery specialist practicing in Bucharest and Tel ...
(Date:6/2/2015)... TapImmune, Inc. (OTCQB: TPIV), a clinical stage cancer immunotherapy ... whereby the institutional investors will have the option to ... up to $4.93M in near term funding, pending closing ... restructured terms and subject to certain market conditions, the ... in a larger influx of capital to fund the ...
Breaking Biology Technology:Circassia to Present at EAACI Annual Meeting, Barcelona, Spain, 6-10 June 2015 2Circassia to Present at EAACI Annual Meeting, Barcelona, Spain, 6-10 June 2015 3Photo-Eyewear™ Changes Name to PogoTec™ and Announces Three Divisions 2Photo-Eyewear™ Changes Name to PogoTec™ and Announces Three Divisions 3Global Stem Cells Group Announces First Stem Cell Training Course to Take Place in Romania 2Global Stem Cells Group Announces First Stem Cell Training Course to Take Place in Romania 3TapImmune Announces Agreement To Facilitate Near Term Capital Infusion; Expediting Path Toward Phase II Trial Initiation 2TapImmune Announces Agreement To Facilitate Near Term Capital Infusion; Expediting Path Toward Phase II Trial Initiation 3
... Today at 5:00 p.m. EDT -, VALENCIA, Calif., ... reported financial results for the first quarter ended,March 31, ... operating expenses were $74.1,million, compared to $77.3 million for ... decreased by $5.3 million to $58.4 million,for the first ...
... Inc. (Nasdaq:,BIOD) today announced that Gerard Michel, Chief Financial ... will present a,corporate update at the Bank of America ... a.m. Pacific Time (12:20 p.m. ET). The conference will,be ... Nevada., Interested parties may access a link to ...
... who helped,explain how embryos develop and form limbs, the ... 2008 March of Dimes Prize in Developmental,Biology., Philip ... share the 2008,March of Dimes Prize for their pioneering ... and their protein signals guide the,formation of the brain, ...
Cached Biology Technology:MannKind Corporation Reports First Quarter Financial Results 2MannKind Corporation Reports First Quarter Financial Results 3MannKind Corporation Reports First Quarter Financial Results 4March of Dimes Awards $250,000 Prize to Leaders in Understanding Embryonic Development 2March of Dimes Awards $250,000 Prize to Leaders in Understanding Embryonic Development 3
(Date:5/14/2015)... and Markets ( http://www.researchandmarkets.com/research/5whpxg/fingerprint ) has announced ... Smart Mobile Devices " report to their offering. ... watershed year for fingerprint sensors in smartphones and tablets, ... fingerprint sensors a raison d,etre in the mobile milieu ... must-have feature in flagship smartphones. The key ...
(Date:5/11/2015)... N.Y. , May 11, 2015 Curemark ... announced the start of a new Phase III double ... of its novel formulation, CM-AT, on all children ages ... of its FDA Phase III double blinded clinical trial ... had low levels of the digestive enzyme chymotrypsin. This ...
(Date:5/6/2015)... LifeBEAM, a developer of bio-sensing technology, and ... that they will expand their partnership in bio-sensing sports ... helmet and the first joint project between the two ... order to give cyclists more style choices and meet ... Lazer announced their plan to release a new generation ...
Breaking Biology News(10 mins):Global Smart Mobile Devices Fingerprint Sensors Market 2015-2019: Key Vendors are Authentec, Validity Sensors, Fingerprint Cards, Next Biometrics Group. IDEX, and Qualcomm 2Curemark, LLC, Launches New Phase III Trial in Expanded Population of Children with Autism 2LifeBEAM and Lazer Announce Expanded Partnership in Bio-Sensing Sports Gear 2LifeBEAM and Lazer Announce Expanded Partnership in Bio-Sensing Sports Gear 3
... GAINESVILLE, Fla. Survival of the fittest has popularly ... new study published in the Royal Society journal Biology ... millions of years may also play a powerful role. ... are the first to link the evolution of proteins ...
... Emory University School of Medicine a three-year grant of more ... that may contribute to the development of autism. Stephen ... Genetics, is principal investigator of the program project that also ... faculty members in human genetics. Autism occurs four ...
... research project, which receives funding from Hope Against ... an extract from bilberries can prevent or delay ... Gescher, of the University of Leicester, is ... with the commercially produced substance Mirtoselect (extracted from ...
Cached Biology News:UF researchers devise way to calculate rates of evolution 2UF researchers devise way to calculate rates of evolution 3Simons Foundation awards Emory scientists $3M for autism gene research 2Bilberry extract -- can it help prevent certain cancers? 2Bilberry extract -- can it help prevent certain cancers? 3
... Xylene Resistant (X/R) Red System consists ... Red Activator and X/R Red Buffer. ... alkaline phosphatase to produce red staining ... ,Kit Contains:, , Buffer, 100 mL ...
Phospho-YAP (Ser127) Antibody Ship: Hot Store: -20 C...
Mouse Cell Line Slides...
... comprehensive, cost-effective solution to your TechMate ... quality into both our products and ... chemistries and antibodies that have been ... also includes our competitively priced accessories ...
Biology Products: